

PCL Department Publications (2009)

Brands B

Elkader A, **Brands B**, Dunn, E. Selby P. and Sproule BA. Major Depressive Disorder and Patient Satisfaction in Relation to Methadone Pharmacokinetics and Pharmacodynamics in Stabilized Methadone Maintenance Patients. *J. Clin Psychopharmacol.* 29(1):77-81. 2009.

Sproule BA, **Brands B**, Selina Li and Catz-Biro L. Changing patterns in opioid addiction: characterizing users of oxycodone and other opioids. *Can Fam Physician.* 55(1): 68-69. 2009.

Elkader A, **Brands B**, Zack, M., Callaghan, R. and Sproule, B.A. Exploring the Relationship Between Perceived Inter-Dose Opioid Withdrawal and Patient Characteristics in Methadone Maintenance Treatment. *Drug Alcohol Depend.* 105: 209-214. 2009.

Anstice S, Strike C and **Brands B**. Supervised methadone consumption: client issues and stigma. *Substance Use Misuse.* 44(6):794-808. 2009.

Toneatto T, **Brands B** and Selby P. A randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of concurrent alcohol abuse/dependence and pathological gambling. *Am J Addict.* 18(3): 219-225. 2009.

Elkader A, **Brands B**, Selby P and Sproule BA. Methadone-Nicotine Interactions in Methadone Maintenance Treatment Patients. *J. Clin Psychopharmacol.* 29: 231-238. 2009

Burnham WM

Taha AY, Alizadeh S, Zeng QH, Filo E, McPherson JP, **Burnham WM**. Assessing the metabolic and toxic effects of anticonvulsant doses of polyunsaturated fatty acids on the liver in rats. *J Toxicol Environ Health A.* 72(19):1191-200. 2009.

Higgins GA, Breyse N, Undzys E, Derksen DR, Jeffrey M, Scott BW, Xin T, Roucard C, Bressand K, Depaulis A, **Burnham WM**. Comparative study of five antiepileptic drugs on a translational cognitive measure in the rat: relationship to antiepileptic property. *Psychopharmacology (Berl).* 207(4):513-27, 2009.

Hum KM, Megna S, **Burnham WM**. Lack of laterality in the effects of right and left amygdala kindling on weight gain in female rats. *Epilepsy Res.* 87(1):40-6. 2009.

Nylen K, Likhodii S, **Burnham WM**. The ketogenic diet: proposed mechanisms of action. *Neurotherapeutics.* 6(2):402-5, 2009.

Taha AY, Henderson ST, **Burnham WM**. Dietary enrichment with medium chain triglycerides (AC-1203) elevates polyunsaturated fatty acids in the parietal cortex of aged dogs: implications for treating age-related cognitive decline. *Neurochem Res.* 34(9):1619-25. 2009.

Hum KM, Megna S, **Burnham WM**. The effects of right and left amygdala kindling on the female reproductive system in rats. *Epilepsia*. 50(4):880-6, 2009.

Nylen K, Velazquez JL, Sayed V, Gibson KM, **Burnham WM**, Snead OC. The effects of a ketogenic diet on ATP concentrations and the number of hippocampal mitochondria in *Aldh5a1*(-/-) mice. *Biochim Biophys Acta*. 1790(3):208-12. 2009.

Taha AY, Filo E, Ma DWL and **Burnham WM**. Dose-dependent anticonvulsant effects of linoleic and α -linolenic polyunsaturated fatty acids on pentylenetetrazol induced seizures in rats. *Epilepsia*. 50 (1): 72-82, 2009.

Taha AY, Ciobanu FA, Saxena A and **Burnham WM**. Assessing the link between omega-3 fatty acids, cardiac arrest, and sudden unexpected death in epilepsy. *Epilepsy Behav*. 14(1): 27-31, 2009.

Chirgadze N

Cardarelli L, Lam R, Tuite A, Baker L, A, Sadowski P D, Radford DR, Rubinstein JL, Battaile KP, **Chirgadze N**, Maxwell KL and Davidson AR. The X-Ray Crystal Structure of Bacteriophage HK97 gp6: Defining a Large Family of Head-Tail Connector Proteins. *J Mol Biol*. 29;395(4):754-68; E. pub 2009 Nov 4.

Dorian P

Laurent G, Leong-Poi H, Mangat I, Korley V, Pinter A, Hu X, So PP, Ramadeen A, **Dorian P**. Influence of ventriculoatrial timing on hemodynamics and symptoms during supraventricular tachycardia. *J Cardiovasc Electrophysiol*. 20(2):176-81, 2009.

Howlett JG, McKelvie RS, Arnold JM, Costigan J, **Dorian P**, Ducharme A. Can Cardiovascular Soc Consensus Conference guidelines on heart failure, update 2009: diagnosis and management of right-sided heart failure, myocarditis, device therapy and recent important clinical trials. *Can J Cardiol*. 25(2):85-105. 2009.

Laurent G, Leong-Poi H, Mangat I, Moe GW, Hu X, So PP, Hennen JK, **Dorian P**. Effects of chronic gap junction conduction-enhancing antiarrhythmic peptide GAP-134 administration on experimental atrial fibrillation in dogs. *Circ Arrhythm Electrophysiol*. 2(2):171-8, 2009.

Posan E, Golovchiner G, **Dorian P**, Pinter A. Three-dimensional bipolar voltage map demonstrating electrical activity of a single muscle bundle along the cavotricuspid isthmus. *Can J Cardiol*. 25(3):e92, 2009.

Dorian P. Effective and efficient use of implantable defibrillators: sometimes it's over when it's over. *CMAJ* 17. 180(6):599-600, 2009.

Connolly SJ, Pogue J, Hart RG, Hohnloser SH, Pfeffer M, Chrolavicius S, Yusuf S. **Dorian P**. – collaborator. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. *N Engl J Med*. 360(20):2066-78, 2009.

Frasure-Smith N, Lespérance F, Habra M, Talajic M, Khairy P, **Dorian P**, Roy D, for the Atrial Fibrillation and Congestive Heart Failure Investigators. Elevated depression symptoms predict long-term cardiovascular mortality in patients with atrial fibrillation and heart failure. *Circulation*. 120(2):134-40, 2009.

Pinter A, Mangat I, Korley V, Connolly S, Connors S, Gardner M, Thibault B, **Dorian P**. Assessment of resynchronization therapy on functional status and quality of life in patients requiring an implantable defibrillator. *Pacing Clin Electrophysiol*. 32(12):1509-19, 2009.

Healey JS, **Dorian P**, Mitchell LB, Talajic M, Philippon F, Simpson C, Yee R, Morillo CA, Lamy A. Canadian registry of ICD implant testing procedures (CREDIT): Current practice, risks, and costs of intra-operative defibrillation testing. *J Cardiovasc Electrophysiol*. 5 2009.

Dorian P, Guerra PG, Kerr CR, O'Donnell SS, Wyse DG. Validation of a new simple scale to measure symptoms in atrial fibrillation: The Canadian Cardiovascular Society Severity in Atrial Fibrillation (CCS-SAF) Scale. *Circ Arrhythm Electrophysiol*. 2(3):218-24, 2009.

Ghosh N, Mangat I, O'Donnell SS, Pinter A, Korley V, Lane C, **Dorian P**. Outcomes in heart failure patients referred for consideration of implantable cardioverter defibrillator (ICD) for primary prophylaxis of sudden cardiac death. *Can J Cardiol*. 25(10):e342-46, 2009.

Massé S, Farid T, **Dorian P**, Umapathy K, Nair K, Asta J, Ross H, Rao V, Sevaptsidis E, Nanthakumar K. Effect of global ischemia and reperfusion during ventricular fibrillation in myopathic human hearts. *Am J Physiol Heart Circ Physiol*. 297(6):H1984-91, 2009.

Thavendiranathan P, Bagai A, Khoo C, **Dorian P**, Coudhry NK. Does this patient with palpitations have a cardiac arrhythmia? *JAMA*. 302(19):2135-43, 2009.

Kowey PR, **Dorian P**, Mitchell LB. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery. *Circ Arrhythm Electrophysiol*. 2(6):652-9, 2009.

Umapathy K, Krishnan S, Hu X, **Dorian P**, Nanthakumar K. Optimizing cardiac resuscitation outcomes using wavelet analysis. *Conf Proc IEEE Eng Med Biol Soc*. 1:6761-4, 2009

Endrenyi L

Endrenyi L and Tothfalusi L. Regulatory conditions for the determination of bioequivalence of highly variable drugs. *J. Pharm. Pharmaceut. Sci*. 12, 138-149 2009.

Tothfalusi L, **Endrenyi L** and Garcia Arieta A. Evaluation of bioequivalence for highly-variable drugs with scaled average bioequivalence. *Clin. Pharmacokin*. 48, 725-743 2009.

Endrenyi L and Tothfalusi L, An illustration of regulatory disharmonization: bioequivalence of highly variable drugs. In: ``New Progress and Challenges in Pharmaceutical Sciences'', A.A. Hincal, N. Celebi, and N. Yuksel, eds. TÜFTAD Pharmaceutical Sciences Series 1, Ankara, pp. 20-33 2009.

Finkelstein Y

Glatstein M, Garcia–Bournissen F, Scolnik D, Koren G and **Finkelstein Y**. TDM Ground Rounds: Hypoglycemia in a healthy toddler. *Therap Drug Monit.* 31:173-7, 2009.

Glatstein M, **Finkelstein Y**, Scolnik D. Accidental methadone ingestion in an infant- case report and review of the literature. *Pediatr Emerg Care.* 25:109-11, 2009.

Finkelstein Y, Nava-Ocampo A, Schechter T, St. Pierre E, Goldman RD, Walker S, Koren G. Discrepancy in Pharmacokinetic Analysis Results by two Standard Population Pharmacokinetic Software Programs. *Fundam Clin Pharmacol.* 23:53-7, 2009.

Garcia Bournissen F, Moretti ME, Juurlink DN, Koren G, Walker M, **Finkelstein Y**. Polymorphism of the ABCB1/ MDR1 C3435T Drug Transporter and Resistance to anticonvulsant Drugs: A Meta-Analysis. *Epilepsia.* 50: 898-903, 2009.

Nussinovitch M, **Finkelstein Y**. Cerebrospinal fluid lactate dehydrogenase isoenzymes in children with bacterial and aseptic meningitis. *Translational Research.* 154(4):214-8. 2009.

Chirnomas D, Smith AL, Braunstein J, **Finkelstein Y**. Deferasirox pharmacokinetics in patients with adequate versus inadequate response. *Blood.* 114(19):4009-13. 2009.

Koren G, **Finkelstein Y**, Matsui D, Berkovich M. Diagnosis and management of poor neonatal adaptation syndrome in newborns exposed in utero to selective serotonin/norepinephrine reuptake inhibitors. *J Obstet Gynaecol Can.* 31(4):348-50. 2009.

Glatstein MM, Garcia-Bournissen F, Giglio N, **Finkelstein Y**, Koren G. Pharmacologic treatment of hyperthyroidism during lactation. *Can Fam Physician.* 55(8):797-8. 2009.

Glatstein MM, Djokanovic N, Garcia-Bournissen F, **Finkelstein Y**, Koren G. Use of hypoglycemic drugs during lactation. *Can Fam Physician.* 55(4):371-3. 2009.

Schechter T, Afzal S, **Finkelstein Y**, Koren G. Daclizumab therapy for children with corticosteroid-resistant acute graft-vs.-host disease. *Pediatric Transplantation.* 13:332-7. 2009.

George SR

So CH, Verma V, Alijaniam M, Cheng R, Rashid AJ, O’Dowd BF, **George SR**. Calcium signaling by dopamine D5 receptors and D5-D2 receptor heterooligomers occurs by a mechanism distinct from that for dopamine D1-D2 receptor heterooligomers. *Mol Pharmacol.* 75: 843-854, 2009.

Hasbi A, Fan T, Alijaniam M, Nguyen T, O’Dowd BF, **George SR**. Dopamine D1-D2 receptor heteromer calcium signaling cascade links striatal BDNF production and neuronal growth. *Proc Nat Acad Sci USA.* 106: 21377-21382, 2009.

Kiehl TR, Chow EWC, Mikulis DJ, **George SR** and Bassett AS. Neuropathologic features in adults with 22q11.2 deletion syndrome. *Cerebral Cortex.* 19: 153-164, 2009.

Hasbi A, O'Dowd BF, **George SR**. Heteromerization of dopamine D2 receptors with dopamine D1 or D5 receptors generates intracellular calcium signaling by different mechanisms. *Curr Opin Pharmacol*. E-Pub Nov 6, 2009.

El-Ghundi M, Fan T, Karasinska J, Yeung J, Zhou M, O'Dowd BF and **George SR**. Restoration of amphetamine induced locomotor sensitization in dopamine D1 receptor deficient mice. *Psychopharmacology*. E-pub Oct 15, 2009.

Sawka AM, Goldstein DP, Brierley JD, Tsang RW, Rotstein L, Ezzat S, Straus S, **George SR**, Abbey S, Rodin G, O'Brien MA, Gafni A, Thabane L, Goguen J, Naeem A, Magalhaes L. The impact of thyroid cancer and post-surgical radioactive iodine treatment on the lives of thyroid cancer survivors: a qualitative study. *Pub Lib Sci (PloS)*. One 4: e4191, 2009.

Ferre S, Baler R, Bouvier M, Caron MG, Devi LA, Durroux T, Fuxe K, **George SR**, Javitch JA, Pflieger KD, Pin J-P, Volkow N, Waldhoer M, Woods AS, Franco R. Building a new conceptual framework for receptor heteromers. *Nature Chem Biol*. 5: 131-134, 2009.

Grad H

Bhalla J, Meechan JG, Lawrence HP, **Grad HA**, Haas DA. Effect of time on clinical efficacy of topical anesthesia. *Anesth Prog*. 56(2):36-41. 2009.

Grant D

McConkey SE, **Grant DM**, Cribb AE. The role of para-aminophenol in acetaminophen-induced methemoglobinemia in dogs and cats. *J Vet Pharmacol Ther*. 32(6):585-95, Dec. 2009.

Robertson GR, **Grant DM**, Piquette-Miller M. Pharmacogenetics of pharmacoecology: which route to personalized medicine? *Clin Pharmacol Ther*. 85(4):343-8; 2009.

Tyndale RF, **Grant DM**, Werner Kalow, MD (1917-2008). The Rich Life of a Poor Metabolizer, In: *Pharmacogenomics – Applications to Patient Care*, 2nd Ed. McLeod HL, DeVane CL, Johnson JA, Knoell DL, Kolesar JM, McInerney JD, Rogers PD, Walker JR. ACCP: Kansas City, Missouri, pp 20-22, 2009.

Hampson D

Chopra M, Yao Y, Blake TJ, **Hampson DR**, Johnson EC. The Neuroactive Peptide NAAG is not an Agonist at the mGluR3 subtype of Metabotropic Glutamate Receptor. *J Pharmacol Exp Therap*. 331(1), 212 - 220. 2009.

Pacey LK, Heximer SP, **Hampson DR**. Increased GABA_B Receptor-mediated Signaling Reduces the Susceptibility of Fragile X Knockout Mice to Audiogenic Seizures. *Mol Pharmacol*. 76 (1), 18-24. 2009.

Rose, EM, Koo JCP, Antflick, JE, Ahmed, SM, Angers S, **Hampson DR**. Glutamate Transporter Coupling to Na,K-ATPase. *J Neurosci*. 29, 8143-55. 2009.

Antflick JE, Vetiska S, Yao Y, Baizer JS, Baker GB, **Hampson DR**. L-Serine-O-phosphate in the central nervous system. *Brain Res*. 1300, 1-13. 2009.

Antflick JE, Baker GB, **Hampson DR**. The Effects of a Low Protein Diet on Amino Acids and Enzymes in the Serine Synthesis Pathway. *Amino Acids*. Nov. 2009; E-pub; DOI 10.1007/s00726-009-0387-8. 2009.

Ito S

Levy S, Fayez I, Taguchi N, Han J-Y, Aiello J, Matsui D, Moretti M, Koren G, **Ito S**. Pregnancy outcome following in utero exposure to bisphosphonates. *Bone*. 44:428-430 2009.

Ito S. Clinical investigation in Pediatrics. *Pediatric Drugs*. 11:67-68, 2009.

De Wildt S, **Ito S**, Koren G. Challenges for pharmacogenetics studies in children: CYP3A phenotyping as an example. *Drug Discovery*. 14:6-15 2009.

Gijzen VMGJ, de Wildt SN, **Ito S**. Probability of rash related to gabapentine therapy in a child. *Ann Pharmacother*. 43:387-389, 2009.

Ito S. Breast cancer risk and history of being breastfed. *Epidemiology*. 20:155, 2009.

Lau A, Duong TT, **Ito S**, Wilson GJ, Young RSM. Inhibition of MMP-9 Activity Improves Coronary Outcome in an Animal Model of Kawasaki Disease. *Clin Exp Immunology*. 157:300-309, 2009.

Lau A, Duong TT, **Ito S**, Young RSM. Intravenous immunoglobulin and salicylate differentially modulate pathogenic processes leading to vascular damage in a model of Kawasaki disease. *Arthritis & Rheumatism*. 60:2131-2141, 2009.

Tanaka T, Nakajima K, Murashima A, Garcia-Bournissen F, Koren G, **Ito S**. Safety of neuraminidase inhibitors, oseltamivir and zanamivir, for pregnant and breastfeeding women during the current pandemic of novel influenza A (H1N1) virus. *CMAJ*. 181:55-58, 2009.

Sakaguchi S, Garcia-Bournissen F, Kim R, Swarcz UI, Nathan PC, **Ito S**. Prolonged Neutropenia after Irinotecan-based Chemotherapy in a Child with polymorphisms of UGT1A1 and SLCO1B1. *Arch Dis Child*. 2009; 94:981-982 (ADC Online doi:10.1136/adc.163089).

Inoue M, Caldarone CA, Frndova H, Cox P, **Ito S**, Taddio A, Guerguerian AM. Safety and efficacy of ketorolac in children after cardiac surgery. *Intensive Care Med*. 35:1584-1592, 2009.

Ross CJD, Katzov-Eckert H, Dube M-P, Brooks B, Rassekh SR, Barhdadi A, Feroz-Zada Y, Visscher H, Brown AMK, Rieder MJ, Rogers PC, Phillips MS, Carleton BC, Hayden MR & CPNDS Consortium. Genetic variants in *TPMT* and *COMT* are associated with hearing loss in children receiving cisplatin chemotherapy. *Nat Genet*. 2009 Dec; 41(12):1345-9. Epub Nov 8, 2009.

Kalant J

Kalant H Addiction: Concepts and Definitions. In: P. Korsmeyer and H.R. Kranzler, eds., Encyclopedia of Drugs, Alcohol, and Addictive Behaviors, 3rd Ed, Vol. 1; Macmillan Reference, pp. 19-28, 2009.

Kish JJ

Boileau I, Guttman M, Rusjan P, Adams JR, Houle S, Tong J, Hornykiewicz O, Furukawa Y, Wilson AA, Kapur S, **Kish SJ**. Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naive Parkinson's disease. *Brain*. 132 (Pt 5):1366-75, 2009

Kish SJ, Fitzmaurice PS, Boileau I, Schmunk GA, Ang LC, Furukawa Y, Chang LJ, Wickham DJ, Sherwin A, Tong J. Brain serotonin transporter in human methamphetamine users. *Psychopharmacology (Berl)*. 202(4):649-61, 2009.

Roedding AS, Gao AF, Wu AM, Li PP, **Kish SJ**, Warsh JJ. TRPC3 protein is expressed across the lifespan in human prefrontal cortex and cerebellum. *Brain Res*. 13; 1260:1-6, 2009.

Koren G (94 papers published in 2009)

de Wildt SN, Ito S, **Koren G**. Challenges for pharmacogenetics studies in children: CYP3A phenotyping as an example. *Drug Discovery*. 14: 6-15, 2009.

Tanaka T, Nakajima K, Murashima A, Garcia-Bournissen F, **Koren G**, Ito S. Safety of neuraminidase inhibitors, oseltamivir and zanamivir for pregnant and breastfeeding women during the current pandemic of novel influenza A (H1N1) virus. *Can Med Assoc J*. 181: 55-58, 2009.

Matok I, Gorodischer R, **Koren G**, Landau D, Wiznitzer A, Levy A. Exposure to folic acid antagonists during the first trimester of pregnancy and the risk of major Mlformations. *Br J Clin Pharmacol*. 68: 956-62, 2009.

Elzagallaai AA, Knowles SR, Rieder MJ, Bend JR, Shear NH, **Koren G**. In vitro testing for the diagnosis of anticonvulsant hypersensitivity syndrome: a systematic review. *Mol Diagn Ther*. 13: 313-30, 2009.

Schoeman K, Bend JR, Hill J, Nash K, **Koren G**. Defining a lowest observable adverse effect hair concentrations of mercury for neurodevelopmental effects of prenatal ethylmercury exposure through maternal fish consumption: a systematic review. *Ther Drug Monit*. 31: 670-82, 2009.

Sarkar M, **Koren G**, Kalra S, Ying A, Smorlesi C, De Santis M, Diav-Citrin O, Avgil M, Voyer Lavigne S, Berkovich M, Einarson A. Montelukast use during pregnancy: a multicentre, prospective, comparative study of infant outcomes. *Eur J Clin Pharmacol*. Aug. 26, 2009.

Ciszkowski C, Madadi P, Phillips MS, Lauwers AE, **Koren G**. Codeine, ultrarapid-metabolism genotype, and postoperative death. *N Engl J Med*. 361: 827-8, 2009.

Nauta M, Landsmeer ML, **Koren G**. Codeine-acetaminophen versus nonsteroidal anti-inflammatory drugs in the treatment of post-abdominal surgery pain: a systematic review of randomized trials. *Am J Surg*. 198: 256-61, 2009.

Greenbaum RL, Stevens SA, Nash K, **Koren G**, Rovet J. Social cognitive and emotion processing abilities of children with fetal alcohol spectrum disorders: a comparison with attention deficit hyperactivity disorder. *Alcohol Clin Exp. Res* 33: 1656-70, 2009.

Thomson S, **Koren G**, Fraser LA, Rieder M, Friedman TC, Van Uum SH. Hair Analysis Provides a Historical Record of Cortisol Levels in Cushing's Syndrome. *Exp Clin Endocrinol Diabetes*. Jul 16, 2009.

Matok I, Gorodischer R, **Koren G**, Sheiner E, Wiznitzer A, Levy A. The safety of metoclopramide use in the first trimester of pregnancy. *N Engl J Med*. 360: 2528-35, 2009.

Gill SK, O'Brien L, Einarson TR, **Koren G**. The safety of proton pump inhibitors (PPIs) in pregnancy: a meta-analysis. *Am J Gastroenterol*. 104: 1541-5, 2009.

Garcia-Bournissen F, Moller M, Nesterenko M, Karaskove T, **Koren G**. Pharmacokinetics of disappearance of cocaine from hair after discontinuation of drug use. *Forensic Sci Int*. 2009 Aug 10;189(1-3):24-7. Epub May 30, 2009.

Lee SW, Han JY, Choic JS, Chung JH, Kim MY, Yang JH, Koong MK, Nava-Ocampo AA, **Koren G**. Pregnancy outcome of women inadvertently exposed to ribostamycin during early pregnancy: a prospective cohort study. *Reprod Toxicol*. 27: 196-8, 2009.

Nguyen P, Tam C, O'Connor DL, Kapur B, **Koren G**. Steady state folate concentrations achieved with 5 compared with 1.1 mg folic acid supplementation among women of childbearing age. *Am J Clin Nutr*. 89: 844-52, 2009.

Kulaga V, Velazquez-Armenta Y, Aleksa K, Vergee Z, **Koren G**. The effect of hair pigment on the incorporation of fatty acid ethyl esters (FAEE). *Alcohol Alcohol*. 44: 287-92, 2009.

Levy S, Fayez I, Taguchi N, Han JY, Aiello J, Matsui D, Moretti M, **Koren G**, Ito S. Pregnancy outcome following in utero exposure to bisphosphonates. *Bone*. 44: 428-30, 2009.

Hutson JR, Aleksa K, Pragst F, **Koren G**. Detection and quantification of fatty acid ethyl esters in meconium by headspace-solid-phase microextraction and gas chromatography-mass spectrometry. *J Chromatogr B Analyt Technol Biomed Life Sci*. 877: 8-12, 2009.

Gill SK, O'Brien L, **Koren G**. The safety of histamine 2 (H2) blockers in pregnancy: a meta-analysis. *Dig Dis Sci*. 54: 1835-8, 2009.

Ratnapalan S, Bentur Y, **Koren G**. "Doctor, will that x-ray harm my unborn child?" *CMAJ*. 179: 1293-6, 2009.

Lanctôt KL

Francis PL, Herrmann N, Tennen G, **Lanctôt KL**. A brief history of post-stroke depression neuroimaging. *Aging Health*. 5(1):79-88. 2009.

Ismail Z, Herrmann N, Francis PL, Rothenburg LS, Lobaugh NJ, Leibovitch FS, Black SE, **Lanctôt KL**. A SPECT study of sleep disturbance and Alzheimer's disease. *Dem Geriatr Cogn Disord*. 27(3):254-259, 2009

Lanctôt KL, Rajaram RD, Herrmann N. Drug therapy for Alzheimer's disease: how effective are current treatments? *Ther Adv Neurolog Disord*. 2(3):163:180, 2009.

Rapoport MJ, **Lanctôt KL**, Streiner DL, Murray B, Schaffer A, Shulman KI, Herrmann N. Benzodiazepines and driving: a meta-analysis. *J Clin Psychiatry*. 70(5):663-73 2009.

Banerji A, **Lanctôt KL**, Paes BA, Masoud S, Tam DY, MacDonald WA, Roberts A. Comparison of the cost of respiratory syncytial virus hospitalization versus palivizumab prophylaxis in term Canadian Inuit infants. *Pediatr Infect Dis J*. 28(8):702-6. 2009.

Banerji A, Greenberg D, Forsberg White L, Macdonald WA, Saxton A, Thomas E, Sage D, Mamdami M, Mahony J, **Lanctôt KL**, Dingle M, Roberts A. Risk factors and viruses associated with hospitalization due to lower respiratory tract infections in Canadian Inuit children: a case-control study *Pediatr Infect Dis*. 28(8):697-701, 2009.

Lanctôt KL, Paes BA, Tarride J-E, Chiu A, Hui C. The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: A Canadian-based analysis *Curr Med Res Opin*. 25:1631-33;2009.

Herrmann N, Rapoport MJ, Rajaram RD, Chan F, Kiss A, Ma AK, Feinstein A, McCullagh S, **Lanctôt KL**. Factor analysis of the Rivermead Post Concussive Symptoms Questionnaire in mild-to-moderate traumatic brain injury patients. *J Neuropsych Clin Neurosci*. 21(2):181-8. 2009.

Rajaram RD, Herrmann N, **Lanctôt KL**. A review of behavioural and psychological symptoms of frontotemporal dementia. *Can Rev Alz Dis Other Dement*. 2(2):9-13, 2009.

Lanctôt KL, Hsiung G-YR, Feldman HH, Masoud ST, Sham L, Herrmann N. Assessing the validity of deriving Clinical Dementia Rating Global scores from independently-obtained Functional Rating Scale scores in vascular dementia with and without Alzheimer's disease. *Int J Geriatr Psychiat*. 24(10):1174-1176, 2009.

Swardfager W, Herrmann N, Dowlati Y, Oh PI, Kiss A, Walker SE, **Lanctôt KL**. Indoleamine 2,3-dioxygenase activation and depressive symptoms in patients with coronary artery disease. *Psychoneuroendocrinology*. 34(10):1560-6, 2009.

Tam D, Banerji A, Paes BA, Hui C, Tarride J-E, **Lanctôt KL**. The cost-effectiveness of palivizumab in term Inuit infants in the eastern Canadian Arctic. *J Med Econ*. 12:361-70., 2009.

Le AD

Lê AD, Funk D, Harding S, Juzytsch W, Fletcher P. The role of noradrenaline and 5-hydroxytryptamine in yohimbine-induced increases in alcohol-seeking in rats. *Psychopharmacology* 204:477-488, 2009.

Marinelli PW, Funk D, Juzytsch W, Harding S, **Lê AD**. Roles of opioid receptor subtypes in mediating alcohol seeking induced by discrete cues and context. *Eur J Neurosci.* 30:671-678, 2009.

Mason BJ, Shaham Y, Weiss F, **Lê AD**. Stress, Alcohol Craving, and Relapse Risk: Mechanisms and Viable treatment targets. *Alcohol.* 47:541-543, 2009.

Ciccocioppo R, Gehlert dr, Ryabinin A, Kaur S, Cippitelli A, Thorsell A, **Lê AD**, Hipskind PA, Hamdouchi C, Lu J, Hembre EJ, Cramer J, Song M, Hommer D, Heilig M. Stress related Neuropeptides and Alcoholism: CRH, NPY and Beyond , *Alcohol.* 47: 491-498, 2009.

Le Foll B

Justinova Z, Ferré S, Barnes C, Wertheim CE, Pappas LA, Goldberg SR, **Le Foll B**. Effects of chronic caffeine exposure on adenosinergic modulation of the discriminative-stimulus effects of nicotine, methamphetamine, and cocaine in rats. *Psychopharmacology (Berl)*; 203(2):355-67, 2009.

Le Foll B, Chefer SI, Kimes AS, Shumway D, Stein EA, Mukhin AG, Goldberg SR. Baseline expression of alpha4beta2 nicotinic acetylcholine receptors predicts motivation to self-administer nicotine. *Biol Psychiatry.* 65(8):714-6, 2009.

Le Foll B, Gallo A, Le Strat Y, Lu L, Gorwood P. Genetics of dopamine receptors and drug addiction: a comprehensive review. *Behav Pharmacol.* 20(1):1-17, 2009.

Le Foll B, Goldberg SR. Effects of nicotine in experimental animals and humans: an update on addictive properties. *Handb Exp Pharmacol.* (192):335-67, 2009.

Le Foll B, Gorelick DA, Goldberg SR. The future of endocannabinoid-oriented clinical research after CB1 antagonists. *Psychopharmacology (Berl)*; 205(1):171-4, 2009.

Forget B, Coen KM, **Le Foll B**. Inhibition of fatty acid amide hydrolase reduces reinstatement of nicotine seeking but not break point for nicotine self-administration--comparison with CB(1) receptor blockade. *Psychopharmacology (Berl)*; 205(4):613-24, 2009.

Shi J, Li SX, Zhang XL, Wang X, **Le Foll B**, Zhang XY, Kosten TR, Lu L. Time-dependent neuroendocrine alterations and drug craving during the first month of abstinence in heroin addicts. *Am J Drug Alcohol Abuse.* 35(5):267-72, 2009.

Novak G, Boukhadra J, Shaikh SA, Kennedy JL, **Le Foll B**. Association of a polymorphism in the NRXN3 gene with the degree of smoking in schizophrenia: a preliminary study. *World J Biol Psychiat.* 10(4 Pt 3):929-35, 2009.

Li PP

Perova T, Kwan M, **Li PP**, Warsh JJ. Differential modulation of intracellular Ca²⁺ responses in B lymphoblasts by mood stabilizers. *Int J Neuropsychopharmacol.* 2010 Jul;13(6):693-702. Epub Apr 29, 2009.

Roedding AS, Gao AF, Wu AM, **Li PP**, Kish SJ, Warsh JJ. TRPC3 protein is expressed across the lifespan in human prefrontal cortex and cerebellum. *Brain Res.* 1260:1-6. Epub Jan 10, 2009.

Xu C, **Li PP**, Cooke RG, Parikh SV, Wang K, Kennedy JL, Warsh JJ. TRPM2 variants and bipolar disorder risk: confirmation in a family-based association study. *Bipolar Disord.* 11(1):1-10, 2009.

Matthews J

Ahmed S, Valen E, Sandelin A, **Matthews J**. Dioxin increases the interaction between aryl hydrocarbon receptor and estrogen receptor alpha at human promoters. *Toxicol Sci.* 111, 254-266, 2009.

Wihlén B, Ahmed S, Inzunza J, **Matthews J**. Estrogen receptor subtype- and promoter-specific modulation of arylhydrocarbon receptor transactivation. *Mol Cancer Res.* 7, 977-986, 2009.

MacPherson L, Lo R, Ahmed S, Pansoy P, **Matthews J**. Activation Function 2 mediates dioxin-induced recruitment of estrogen receptor alpha to CYP1A1 and CYP1B1. *Biochem Biophys Res Comm.* 385, 263-268, 2009.

McIntyre RS

Kim B, Kim S, **McIntyre RS**, Park HJ, Kim SY, Joo YH. Correlates of metabolic abnormalities in bipolar I disorder at initiation of acute phase treatment. *Psychiatry Investig.* 6(2):78-84, 2009.

McIntyre RS, Muzina DJ, Adams A, Nathanson J, Kennedy SH. Quetiapine XR efficacy and tolerability as monotherapy and as adjunctive treatment to conventional antidepressants in the acute and maintenance treatment of major depressive disorder: a review of registration trials. *Expert Opin Pharmacother.* 10 (18):3061-75 2009.

McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. *Bipolar Disord.* 11(7):673-86, 2009.

Kirchhoff VD, Nguyen HT, Soczynska JK, Woldeyohannes H, **McIntyre RS**. Discontinued psychiatric drugs in 2008. *Expert Opin Investig Drugs.* 18(10):1431-43, 2009.

Lam RW, Kennedy SH, Grigoriadis S, **McIntyre RS**, Milev R, Ramasubbu R, Parikh SV, Patten SB, Ravindran AV. Canadian Network for Mood and Anxiety Treatments (CANMAT). CANMAT clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. *J Affect Disord.* 117 Suppl 1:S26-43, 2009.

McIntyre RS. Managing weight gain in patients with severe mental illness. *J Clin Psychiatry.* 70(7):e23, 2009.

Alsuwaidan MT, Kucyi A, Law CW, **McIntyre RS.** Exercise and bipolar disorder: a review of neurobiological mediators. *Neuromolecular Med.* 11(4):328-36, 2009.

McIntyre RS. Understanding needs, interactions, treatment, and expectations among individuals affected by bipolar disorder or schizophrenia: the UNITE global survey. *J Clin Psychiatry.* 70 Suppl 3:5-11, 2009.

McIntyre RS. Introduction: Balancing the equation: managing comorbidities in patients with severe mental illness. *J Clin Psychiatry.* 70 Suppl 3:4, 2009.

McIntyre RS. Overview of managing medical comorbidities in patients with severe mental illness. *J Clin Psychiatry.* 70(6):e17, 2009.

Kemp DE, Canan F, Goldstein BI, **McIntyre RS.** Long-acting risperidone: a review of its role in the treatment of bipolar disorder. *Adv Ther.* 26(6):588-99, 2009.

Goldstein BI, Kemp DE, Soczynska JK, **McIntyre RS.** Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. *J Clin Psychiatry.* 70(8):1078-90, 2009.

Soczynska JK, Kennedy SH, Goldstein BI, Woldeyohannes HO, **McIntyre RS.** The effect of tumor necrosis factor antagonists on mood and mental health-associated quality of life: novel hypothesis-driven treatments for bipolar depression? *Neurotoxicology.* 30(4):497-521, 2009.

Konarski JZ, Kennedy SH, Segal ZV, Lau MA, Bieling PJ, **McIntyre RS,** Mayberg HS. Predictors of nonresponse to cognitive behavioural therapy or venlafaxine using glucose metabolism in major depressive disorder. *J Psychiatry Neurosci.* 34(3):175-80, 2009.

Baghdady NT, Banik S, Swartz SA, **McIntyre RS.** Psychotropic drugs and renal failure: translating the evidence for clinical practice. *Adv Ther.* 26(4):404-24, 2009.

McIntyre RS. Review: non-pharmacological interventions reduce antipsychotic induced weight gain. *Evid Based Ment Health.* 12(2):52, 2009.

Nguyen HT, Sharma V, **McIntyre RS.** Teratogenesis associated with antibipolar agents. *Adv Ther.* 26(3):281-94, 2009.

Jerrell JM, **McIntyre RS.** Cardiovascular and neurological adverse events associated with antidepressant treatment in children and adolescents. *J Child Neurol.* 24(3):297-304, 2009.

McIntyre RS, Jerrell JM. Polypharmacy in children and adolescents treated for major depressive disorder: a claims database study. *J Clin Psychiat.* 70(2):240-6, 2009.

McIntyre RS, Rasgon NL, Kemp DE, Woldeyohannes HO, Alsuwaidan MT, Soczynska JK, Kim B, Lourenco MT, Kahn LS, Goldstein BI. Metabolic syndrome and major depressive disorder: co-occurrence and pathophysiologic overlap. *Curr Diab Rep.* 9(1):51-9, 2009.

Law CW, Soczynska JK, Woldeyohannes HO, Miranda A, Brooks JO 3rd, **McIntyre RS**. Relation between cigarette smoking and cognitive function in euthymic individuals with bipolar disorder. *Pharmacol Biochem Behav.* 92(1):12-6, 2009.

McPherson JP

McPherson JP, Sarras H, Lemmers B, Migon E, Matysiak-Zablocki E, Hakem A, Calarco JA, Alizadeh Azami S, Cardoso R, Tamblyn L, Fish J, Sanchez O, Post M, Hakem R. Essential role for *Bclaf1* in lung development and immune system function. *Cell Death Differen.* 16: 331-339; 2009.

Tamblyn L, Li E, Sarras H, Srikanth P, Hande MP, **McPherson JP**. A role for *Mus81* in the repair of chromium-induced DNA damage. *Mutat. Res.* 660:57-65, 2009.

Taha AY, Alizadeh S, Zeng QH, **McPherson JP**, Burnham WM. Assessing metabolic and toxic effects of polyunsaturated fatty acids at anticonvulsant doses in rat liver. *J. Toxicol. and Environ. Health.* 72:1191-1200; 2009.

Meyer JH

Meyer JH, Wilson AA, Sagrati S, Miler L, Rusjan P, Bloomfield PM, Clark M, Sacher J, Voineskos AN, House S: Brain monoamine oxidase A binding in major depressive disorder: relationship to selective serotonin reuptake inhibitor treatment, recovery, and recurrence. *Arch Gen Psychiat.* 66 (12): 1304-12, 2009.

Mitchell J

Hong SHH, Lu X, Names SM, **Mitchell J**. Regulation of *osterix (Osx, Sp7)* and the *Osx* promoter by parathyroid hormone in osteoblasts. *J Mol Endo.* 43:197-207, 2009.

Tong D, Rozas N, Oakley T, **Mitchell J**, Colley N, McFall-Ngai M. Evidence for light perception in a bioluminescent organ. *Proc Natl Acad Sci USA.* 106:9836-41, 2009.

Lai LP, **Mitchell J**. Parathyroid hormone inhibits phosphorylation of mitogen-activated protein kinase (MAPK) ERK1/2 through inhibition of *c-Raf* and activation of *MKP-1* in osteoblastic cells. *Cell Biochem Funct.* 27(5):269-75, 2009.

Mittmann N

Chan B, Hales B, Shear NH, Ho V, Lynde C, Poulin Y, **Mittmann N**. Work Related Lost Productivity and its Economic Impact in Canadian Patients with Moderate to Severe Psoriasis. *J Cutaneous Medicine & Surgery.* 13(4): 192-7, 2009.

Bessette L, Risebrough N, **Mittmann N**, Roussy JP, Ho J, Zlateva G. The Cost of Utility of Celecoxib Use in Different Treatment Strategies for Osteoarthritis and Rheumatoid Arthritis from the Quebec Healthcare System Perspective. *J Med Economics*. 12(3): 246-258, 2009.

Mittmann N, Au HJ, Tu D, O'Callaghan CJ and the Working Group in Economic Analysis of the National Cancer Institute of Canada Clinical Trials Group. Prospective Cost-Effectiveness Analysis of Cetuximab in Metastatic Colorectal Cancer: Evaluation of NCIC CO.17 Trial. *J Nat Cancer Inst*. 101(17): 1182-1192, 2009.

Mittmann N, Knowles S. Pharmacy and Therapeutic Committees across Canada: scope and responsibilities. *Can J Clin Pharmacol*. 16 (1): e171-e177; 2009.

Cheung MC, Imrie KR, Friedlich J, Buckstein R, Lathia N, **Mittmann N**. The Impact of follicular and other indolent non-Hodgkin's lymphomas on work productivity – a preliminary analysis. *Psycho-Oncology*. 18(5): 554-559, 2009.

Neuman MG

Oz HS, Chen TS, **Neuman M**. Nutrition intervention: a strategy against systemic inflammatory syndrome. *J Parenter Enteral Nutr*. 33(4):380-9, 2009.

Miele L, Forgione A, La Torre G, Vecchio FM, Gasbarrini G, Rapaccini GL, **Neuman MG**, Grieco A. Serum levels of hyaluronic acid and tissue metalloproteinase inhibitor-1 combined with age predict the presence of nonalcoholic steatohepatitis in a pilot cohort of subjects with non-alcoholic fatty liver disease. *Transl Res*. 154(4):194-201, 2009.

Rehm J, Samokhvalow AW, **Neuman MG**, Room R, Parry CD, Lönnroth K, Patra J, Poznyak V, Popova S: The association between alcohol use, alcohol use disorders and tuberculosis (TB). A systematic review. *BMC Public Health*. 5, 9:450, 2009

Neuman MG, Steenkamp V: Toxicity profile of pyrrolizidine alkaloid-containing medicinal plants: Emphasis on *Senecio* Species. *Indian J of Biological Sciences, Int J Biomed and Pharmaceut Sci*. 3 (1): 13, 26-30 104-108 for IJBPS-11 and 13-2009.

Neuman MG, Winkler, R. Liver-Induced Damage by Traditional Herbal Remedies. *Rev Rom Hepatol*. 4, (23), 39-51, 2009

Neuman MG, Erlinger S. Jean-Pierre Benhamou, a tribute (July 13, 1927 to September 17, 2008). *Hepatology*, 49(3), 709-710, 2009.

Neuman MG Obituary Charles S. Lieber 13th February 1931 - 1st March 2009, *J. Hepatology*. 51(3), 421-422, 2009.

Nobrega JN

Harrison SJ and **Nobrega JN**. Differential susceptibility to ethanol and amphetamine sensitization in dopamine D3 receptor-deficient mice. *Psychopharmacology*, 204, 49-59, 2009

Sander SE, Richter R, Raymond R, Diwan M, Lange N, **Nobrega JN** Richter A. Pharmacological and autoradiographic studies on the pathophysiological role of GABA(b) receptors in the dystonic hamster: pronounced antidystonic effects of baclofen after striatal injections. *Neuroscience*, 162, 423-430, 2009.

Rabiner EA, Slifstein M, **Nobrega JN**, Plisson, C., Huiban, M., Raymond, R., Diwan, M., Wilson, A., McCormick, P., Gentile, G., Gunn, R.N. and Laruelle, M.A. Quantification of regional dopamine-D3 receptor components of (+)-PHNO binding in vivo: Primate PET with [¹¹C]-(+)-PHNO and mouse autoradiography with ³H-(+)-PHNO. *Synapse*, 63, 782-793, 2009.

Palma BD, Tufik S, **Nobrega JN**, Gomes VL, Esumi LA, Seabra MV and Hipolide DC. Prostaglandin involvement in hyperthermia induced by sleep deprivation: a pharmacological and autoradiographic study. *Life Sci.* 84, 278-281, 2009.

Chintoh AF, Mann SW, Lam L, Giacca A, Fletcher P, **Nobrega JN** and Remington G. Insulin resistance and secretion in vivo: Effects of different antipsychotics in an animal model. *Schizophrenia Res.* 108, 127-133, 2009.

Harrison SJ and **Nobrega JN**. A functional role for the dopamine D3 receptor in the induction and expression of behavioural sensitization to ethanol in mice. *Psychopharmacology*, 207, 47-56, 2009.

O'Brien PJ

McKeown-Eyssen G, Bruce J, Lee O, **O'Brien, PJ**, Bruce WR. Lifestyle, endogenous toxins and colorectal cancer risk. In: "Endogenous Toxins, diet, genetics, disease and treatment". Eds: PJ O'Brien and WR Bruce, STS Books; Wiley-VCH; pp 673-6, 2009.

Corpet DE, Guéraud F, **O'Brien, PJ**. Iron from meat produces endogenous pro-carcinogen peroxides. In: "Endogenous Toxins, diet, genetics, disease and treatment". Eds: PJ O'Brien and WR Bruce, STS Books; Wiley-VCH; pp 133-149, 2009.

O'Brien, PJ, Feng CY, Lee O, Mehta R, Bruce J, Bruce WR. Fructose-derived endogenous toxins In: "Endogenous Toxins, diet, genetics, disease and treatment". Eds: PJ O'Brien and WR Bruce, STS Books; Wiley-VCH; pp 173-212, 2009.

Feng C and **O'Brien PJ**. Hepatocyte inflammation model for cytotoxicity research: fructose or glycolaldehyde as a source of endogenous toxins. *Arch Physiol Biochem.* 115(2),105-111, 2009.

Truong D, Hindmarsh W and **O'Brien PJ**. The molecular mechanisms of diallyl disulfide and diallyl sulfide induced hepatocyte cytotoxicity. *Chemico-Biol. Interact.* 180,79-88, 2009.

Mehta R, Wong L and **O'Brien PJ**. Cytoprotective mechanisms of carbonyl scavenging drugs in isolated rat hepatocytes. *Chemico-Biol. Interact.* 178, 317-23, 2009.

Lee O, Bruce WR, Dong Q, Bruce J, Mehta R and **O'Brien PJ**. Fructose and carbonyl metabolites as endogenous toxins. *Chemico-Biol. Interact.* 178, 332-9, 2009.

Banach MS, Dong Q and **O'Brien PJ**. Hepatocyte Cytotoxicity Induced by Hydroperoxide (Oxidative stress) or Glyoxal (Protein Carbonylation Model): Prevention by Bioactive Nut Extracts or Catechins. *Chemico-Biol. Interact.* 178, 324-31, 2009.

Tafazoli S and **O'Brien PJ**. Amodiaquine-induced oxidative stress in a hepatocyte inflammation model *Toxicology* 256, 101-9, 2009.

Martin JW, Chan K, Mabury SA, **O'Brien PJ**. Bioactivation of Fluorotelomer Alcohol in Isolated Rat Hepatocytes. *Chemico-Biol. Interact.* 177, 196-203, 2009.

Chan TS, Wilson JX, Selliah S, Bilodeau M, Zwingmann C, Poon R and **O'Brien PJ**. Organochlorines inhibit acetaminophen glucuronidation by redirecting UDP-glucuronic acid towards the D-glucuronate pathway. *Toxicol. Appl. Pharmacol.* 232, 456-62, 2009.

O'Dowd BF

Hasbi A, Fan T, Alijaniam M, Nguyen T, Perreault ML, **O'Dowd BF**, George SR. Calcium signaling cascade links dopamine D1-D2 receptor heteromer to striatal BDNF production and neuronal growth. *Proc Natl Acad Sci USA.* 15; 106(50): 21377-82, 2009.

So CH, Verma V, Alijaniam M, Cheng R, Rashid AJ, **O'Dowd BF**, George SR. Calcium signaling by dopamine D5 receptor and D5-D2 receptor hetero-oligomers occurs by a mechanism distinct from that for dopamine D1-D2 receptor hetero-oligomers. *Mol Pharmacol.* 75(4):843-54, 2009.

Pang KS

Pang KS, Maeng HJ, Fan J. Interplay of transporters and enzymes in drug and metabolite processing. *Mol Pharm.* 6(6):1734-55, 2009.

Chow EC, Maeng HJ, Liu S, Khan AA, Groothuis GM, **Pang KS**. 1 α , 25-Dihydroxyvitamin D(3) triggered vitamin D receptor and farnesoid X receptor-like effects in rat intestine and liver in vivo. *Biopharm Drug Dispos.* 30(8):457-75, 2009.

Khan, A.A. Chow E.CY. van Loenen-Weemaes A.M.A., Porte R. J., **Pang, K.S.** and Groothuis G.M.M. Comparison of VDR versus PXR, FXR and GR on the regulation of CYP3A isozymes in rat and human intestine and liver. *Eur J. Pharm. Sci.* 37:115-125, 2009.

Fan J, Liu S, Du Y, Morrison J, Shipman R, **Pang KS**. Up-regulation of transporters and enzymes by the vitamin D receptor ligands, 1 α ,25-dihydroxyvitamin D3 and vitamin D analogs, in the Caco-2 cell monolayer. *J Pharmacol Exp Ther.* 330(2):389-402, 2009.

Khan AA, Chow E.CY, **Pang KS** and Groothuis GMM. Expression and regulation of the bile acid efflux transporters, Ost α -Ost β , in rat intestine and liver. *Biopharm. Drug Dispos.* 30:241-258, 2009.

Sun H, **Pang KS**. Disparity in intestine disposition between formed and preformed metabolites and implications: a theoretical study. *Drug Metab Dispos.* 37(1):187-202, 2009.

Pang KS. Safety testing of metabolites: Expectations and outcomes. *Chem Biol Interact.* 5; 179(1):45-59, 2009.

Pace-Asciak CR

Pace-Asciak CR. The hepoxilins and some analogues: a review of their biology. *Br J Pharmacol.* 158(4): 972-81, 2009.

Park H-W

Tong Y, Tempel W, Nedyalkova L, MacKenzie F, **Park H-W.** Crystal structure of the N-acetylmannosamine kinase domain of GNE. *PLoS One*, 4(10):e7165, 2009.

Allali-Hassani A, Wasney GA, Chau I, Shi Z, Moulton J, Edwards AM, Arrowsmith CH, **Park H-W**, Schapira M, Vedadi M. A survey of proteins encoded by non-synonymous SNPs reveals a significant fraction with altered stability and activity. *Biochemical J.* 424:15-26, 2009.

Tong Y, Hota PK, Penachioni JY, Bagheri-Hamaneh M, Kim SJ, Alviani R, Shen L, He H, Tempel W, Tamagnone L, **Park H-W**, Buck M. Structure and function of the intracellular region of the plexin-b1 transmembrane receptor. *JBC.* 284:35962-35972, 2009.

Tong Y, Park I, Hong BS, Nedyalkova L, Tempel W, **Park H-W.** Crystal structure of human eIF5A1: Insight into functional similarity of human eIF5A1 and eIF5A2. *Proteins: Structure, Function, and Bioinformatics*, 75:1040-1045, 2009.

Petronis A

Kaminsky ZA, Tang T, Wang SC, Ptak C, Oh G, Wong AHC, Feldcamp LA, Virtanen C, Halfvarsson J, Tysk C, McRae A, Visscher P, Montgomery GW, Gottesman II, Martin NG, and **Petronis A.** DNA methylome studies in twins, *Nature Genetics* 41, 240-245, 2009.

Mill J, **Petronis A.** Profiling DNA methylation from small amounts of genomic DNA starting material: efficient sodium bisulfite conversion and subsequent whole-genome amplification. *Methods Mol Biol.* 507:371-81, 2009.

Kaminsky Z, **Petronis A.** Methylation SNaPshot: A Method for the Quantification of Site-Specific DNA Methylation Levels. *Methods Mol Biol.* 507:241-55, 2009.

Flanagan JM, Munoz-Alegre M, Henderson S, Tang T, Sun P, Johnson N, Fletcher O, Santos Silva I, Peto J, Boshoff C, Narod S, **Petronis A.** Gene body hypermethylation of ATM in peripheral blood DNA of bilateral breast cancer patients. *Human Molecular Genetics*, 18(7):1332-42, 2009.

Ramsey AJ

Ghisi V, **Ramsey AJ**, Masri B, Gainetdinov RR, Caron MG, Salahpour A. Reduced D2-mediated signaling activity and trans-synaptic upregulation of D1 and D2 dopamine receptors in mice overexpressing the dopamine transporter. *Cell Signal*. 21(1):87-94, 2009.

Kocerha J, Faghihi MA, Lopez-Toledano MA, Huang J, **Ramsey AJ**, Caron MG, Sales N, Willoughby D, Elmen J, Hansen HF, Orum H, Kauppinen S, Kenny PJ, Wahlestedt C. MicroRNA-219 modulates NMDA receptor-mediated neurobehavioral dysfunction. *Proc Natl Acad Sci U S A*. 106(9):3507-3512, 2009.

Maldonado-Avilés JG, Curley AA, Hashimoto T, Morrow AL, **Ramsey AJ**, O'Donnell P, Volk DW, Lewis DA. Altered markers of tonic inhibition in the dorsolateral prefrontal cortex of subjects with schizophrenia. *Am J Psychiat*. 166(4):450-459, 2009.

Dzirasa K, **Ramsey AJ**, Takahashi DY, Stapleton J, Potes JM, Williams JK, Gainetdinov RR, Sameshima K, Caron MG, Nicolelis MA. Hyperdopaminergia and NMDA receptor hypofunction disrupt neural phase signaling. *J Neurosci*. 24;29(25):8215-8224, 2009.

Ramsey AJ. NR1 knockdown mice as a representative model of the glutamate hypothesis of schizophrenia. *Prog Brain Res*. 179:51-58, 2009.

Riddick DS

Mullen Grey AK, **Riddick DS**. Glucocorticoid and adrenalectomy effects on the rat aryl hydrocarbon receptor pathway depend on the dosing regimen and post-surgical time. *Chem.-Biol. Interact*. 182: 148-158, 2009.

Salahpour A

Ghisi V, Ramsey AJ, Masri B, Gainetdinov RR, Caron MG, **Salahpour A**. Reduced D2-mediated signaling activity and trans-synaptic upregulation of D1 and D2 dopamine receptors in mice overexpressing the dopamine transporter. *Cell Signal*. 21(1):87-94, 2009.

Schapira M

Campagna-Slater V, **Schapira M**. Evaluation of virtual screening as a tool for chemical genetic applications; *J Chem Inf Model*. 49(9):2082-91, 2009.

Allali-Hassani A, Wasney GA, Chau I, Hong BS, Senisterra G, Loppnau P, Shi Z, Moulton J, Edwards AM, Arrowsmith CH, Park H-W, **Schapira M**, Vedadi M. A survey of proteins encoded by non-synonymous SNPs reveals a significant fraction with altered stability and activity; *Biochem J*. 23;424(1):15-26, 2009.

Guo Y, Nady N, Qi C, Allali-Hassani A, Zhu H, Pan P, Adams-Cioaba MA, Amaya MF, Dong A, Vedadi M, **Schapira M**, Read RJ, Arrowsmith CH, Min J. Methylation-state-specific recognition of histones by the MBT repeat protein L3MBTL; *Nucleic Acids Res.* 237(7):2204-10, 2009.

Qiu W, Wernimont A, Tang K, Taylor S, Lunin V, **Schapira M**, Fentress S, Hui R, Sibley LD. Novel structural and regulatory features of rhoptry secretory kinases in *Toxoplasma gondii*; *EMBO J.* 8;28(7):969-79, 2009.

Huang X, Finerty P Jr, Walker JR, Butler-Cole C, Vedadi M, **Schapira M**, Parker SA, Turk BE, Thompson DA, Dhe-Paganon S. Structural insights into the inhibited states of the Mer receptor tyrosine kinase; *J Struct Biol.* 165(2):88-96, 2009.

Schimmer BP

Schimmer BP: Keith Langston Parker (1954-2008). *Cell Metab.* 115-116, 2009.

Seeman P

Seeman P: Glutamate and dopamine components in schizophrenia. *J. Psychiatry Neurosci.* 34(2): 143-149, 2009.

Seeman P, Battaglis G, Corti C, Nicoletti F, Bruno V: Glutamate receptor mGlu2 and mGlu3 knockout striata are dopamine supersensitive, with elevated D2^{High} receptors and marked supersensitivity to the dopamine agonist (+)PHNO. *Synapse*, 63: 247-251, 2009.

Seeman P: Dopamine D2^{High} receptors measured *ex vivo* are elevated in amphetamine-sensitized animals. *Synapse*, 63: 186-192, 2009.

King MV, **Seeman P**, Marsden CA, Fone KCF: Increased dopamine 2^{High} receptors in rats reared in social isolation. *Synapse*, 63: 476-483, 2009.

Seeman P, Tokita K, Matsumoto M, Matsuo A, Sasamata M, Miyata K: The dopaminergic stabilizer ASP2314/ACR16 selectively interacts with D2^{High} receptors. *Synapse*, 63: 930-934, 2009.

Alttoa A, **Seeman P**, Kõiv K, Eller M, Harro J: Rats with persistently high exploratory activity have both higher extracellular dopamine levels and higher proportion of D2^{High} receptors in the striatum. *Synapse*, 63: 443-446, 2009.

Seeman P, Guan H-C and Hirbec J: Dopamine D2^{High} receptors stimulated by phencyclidines, LSD, salvinorin A, and modafinil. *Synapse*, 63(8):698-704, 2009.

Seeman P: Glutamate agonists for treating schizophrenia have affinity for dopamine D2^{High} and D3 receptors. *Synapse*, 63(8): 705-709, 2009.

Seeman P and Guan H-C: Glutamate agonist LY 404,039 for treating schizophrenia has affinity for the dopamine D2^{High} receptor. *Synapse*, 63: 935-939, 2009.

Seeman P: Schizophrenia model of elevated D2^{High} receptors: Haloperidol reverses the amphetamine-induced elevation in dopamine D2^{High}. *Schizophrenia Res.* 91: 191-192, 2009.

Robinson T, Volman S and **Seeman P:** Chronic cocaine increases high-sensitivity D2 receptors. *NIDA Notes, Natl. Inst. Drug Abuse* 22(5), 2009.

Sellers EM

Al Koudsi NA, Ahluwalia JS, Shih-Ku L, **Sellers EM**, Tyndale RF. A novel CYP2A6 allele (CYP2A6*35) resulting in an amino-acid substitution (Asn438Tyr) is associated with lower CYP2A6 activity in vivo. *Pharmacogenomics J.* 9(4): 274-282, 2009.

Roth W, Setnik B, Zietsch, Burst A, Breitenbach, **Sellers EM**, Brennan D. Ethanol effects on drug release from Verapamil Meltrex®, an innovative melt extruded formulation. *Int J Pharm.* 368(1-2): 72-75, 2009.

Stauffer J, Setnik B, Sokolowska M, Romach M, Johnson F, **Sellers EM**. Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended release capsules versus morphine sulfate solution and placebo in experienced non-dependent opioid users: A randomized, double-blind, placebo-controlled, crossover study. *Clin Drug Invest.* 29(12): 777-790, 2009.

Semple JW

Kjeldsen-Kragh J, Kim M, Kjær Killie M, Husebekk A, Freedman J, **Semple JW**. In HPA 1a-immunized women the decrease in anti-HPA 1a antibody level during pregnancy is not associated with anti-idiotypic antibodies. *Haematologica,* 94(3):441-443, 2009

Semple JW, Freedman J: Platelets and Innate Immunity. *Cell Mol Life Sci.* 67(4):499–511, 2009.

Semple JW. Infections, Antigen Presenting Cells, T cells and Immune Tolerance: Their Role in the Pathogenesis of Immune Thrombocytopenia (ITP). *Hematol Oncol Clinics N Amer.* 23(6): 1177-1192, 2009.

Semple JW: Platelet antigen-induced regulation in ITP. *Blood* 113(11):2373, 2009.

Semple JW: Processed Platelet HPA1a peptides au naturel. *Blood.* 114(9):1724–1725, 2009.

Semple JW: ITP has elevated BAFF Expression. *Blood* 114(26):5248-5449, 2009.

Snead OC

Sugiyama I, Imai K, Yamaguchi Y, Akizuki Y, Go C, Akiyama T, **Snead OC**. Localization of epileptic foci in children with intractable epilepsy secondary to multiple cortical tubers by using synthetic aperture magnetometry kurtosis. *J Neurosurg Pediatr.* 4(6):515-22, 2009.

Benifla M, Sala F Jr, Jane J, Holowka S, Widjaja E, **Snead OC**, Smith ML, Tamber MS, Rutka JT. Neurosurgical management of intractable rolandic epilepsy in children: role of resection in eloquent cortex. Clinical article. *J Neurosurg Pediatr.* 4 (3):199-216, 2009.

Pang EW, Gaetz W, Drake JM, Strantzas S, MacDonald MJ, Otsubo H, **Snead OC**. Patient with postcentral gyrectomy demonstrates reliable localization of hand motor area using magnetoencephalography. *Pediatr Neurosurg.* 45(4):311-6, 2009.

Wang X, Stewart L, Cortez MA, Wu Y, Velazquez JL, Liu CC, Shen L, **Snead OC**. The circuitry of atypical absence seizures in GABA(B)R1a transgenic mice. *Pharmacol Biochem Behav.* 94(1):124-30 2009.

Stewart LS, Wu Y, Eubanks JH, Han H, Leschenko Y, Perez Velazquez JL, Cortez MA, **Snead OC**. Severity of atypical absence phenotype in GABAB transgenic mice is subunit specific. *Epilepsy Behav.* 14(4):577-81 2009.

Kadis DS, Kerr EN, Rutka JT, **Snead OC**, Weiss SK, Smith ML. Pathology type does not predict language lateralization in children with medically intractable epilepsy. *Epilepsia*,50(6):1498-504 2009.

Cortez MA, Shen L, Wu Y, Aleem IS, Trepanier CH, Sadeghnia HR, Ashraf A, Kanawaty A, Liu CC, Stewart L, **Snead OC**. Infantile spasms and Down syndrome: A ew animal model. *Pediatr Res.* 65(5):499-503 2009.

Widjaja E, Zarei Mahmoodabadi S, Otsubo H, **Snead OC**, Holowka S, Bells S, Raybaud C. Subcortical alterations in tissue microstructure adjacent to focal cortical dysplasia: detection at diffusion-tensor MR imaging by using magnetoencephalographic dipole cluster localization. *Radiology.* 251(1):206-15 2009.

Nylen K, Velazquez JL, Sayed V, Gibson KM, Burnham WM, **Snead OC**. The effects of a ketogenic diet on ATP concentrations and the number of hippocampal mitochondria in *Aldh5a1*(-/-) mice. *Biochim Biophys Acta.* 1790(3):208-12 2009.

Yamazaki M, Chan D, Tovar-Spinoza Z, Widjaja E, Matsuura M, **Snead OC**, Otsubo H. Interictal epileptogenic fast oscillations on neonatal and infantile EEGs in hemimegalencephaly. *Epilepsy Res.* 83(2-3):198-206 2009.

Huo JZ, Cortez MA, **Snead OC**. GABA receptor proteins within lipid rafts in the AY-9944 model of atypical absence seizures. *Epilepsia.* 50(4):776-88 2009.

Bercovici E, Cortez MA, Wang X, **Snead OC**. Monoamine variability in the chronic model of atypical absence seizures. *Epilepsia.* 50(4):768-75 2009.

Tyndale RF

Miksys SL, Tyndale RF. *In vivo* brain cytochrome P450 activity demonstrated by mechanism-based enzyme inhibition. *Neuropsychopharmacology.* 34(3): 634-40, 2009.

Schnoll RA, Patterson F, Wileyto EP, **Tyndale RF**, Benowitz N, Lerman C. Nicotine Metabolic Rate Predicts Successful Smoking Cessation with Transdermal Nicotine: A Validation Study. *Pharmacol Biochem Behavior*. 92(1):6-11, 2009.

Swan GE, Lessov-Schlaggar CN, Bergen AW, He Y, Wilhelmsen K, **Tyndale RF** and Benowitz NL. Genetic and environmental influences on the ratio of 3'hydroxycotinine to cotinine in plasma and urine. *Pharmacogenetics Genomics*, 19(5)388-398, 2009.

Thomas P, Mi H, Swan G, Lerman C, Benowitz N, **Tyndale RF**, Conti D. A systems biology network model for genetic association studies of the pharmacogenetics of nicotine addiction and treatment. *Pharmacogenetics Genomics*, 19(7): 538-551, 2009.

Yue J, Khokhar J, Miksys SL, **Tyndale RF**. Differential induction of ethanol-metabolizing CYP2E1 and nicotine-metabolizing CYP2B1/2 in rat liver by chronic nicotine treatment and ethanol self-administration. *Eur J Pharmacol*. 609(1-3): 88-95, 2009.

Ho MK, Mwenifumbo JC, Al Koudsi N, Okuyemi KS, Ahluwalia JS, Benowitz NL, **Tyndale RF**. Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers. *Clin Pharmacol Ther*. 85(6): 635-43, 2009.

Miksys SL and **Tyndale RF**. Brain and disease: The long path to discovery and treatment. Editorial; *Clin Pharmacol Ther*. 86(4):343-346, 2009.

Al Koudsi N, Ahluwalia JS, Lin SK, Sellers EM, **Tyndale RF**. A novel CYP2A6 allele (CYP2A6*35) resulting in an amino acid substitution (N438Y) is associated with lower CYP2A6 activity in vivo. *The Pharmacogenomics J*. 9(4): 274-82, 2009.

Bergen AW, Conti DV, Van Den Berg D, Lee W, Liu J, Li D, Guo N, Mi H, Thomas PD, Lessov-Schlaggar CN, Krasnow R, He Y, Nishita D, Jiang R, McClure JB, Tildesley E, Hops H, **Tyndale RF**, Benowitz NL, Lerman C, Swan GE. Dopaminergic genes and nicotine dependence in treatment seeking and community smokers. *Neuropsychopharmacology*, 34: 2252-64, 2009.

Ho MK, Faseru B, Choi WS, Nollen NL, Mayo MS, Thomas JL, Okuyemi KS, Ahluwalia JS, Benowitz NL, **Tyndale RF**. Utility and relationships of biomarkers of smoking in African-American light smokers. *Cancer Epidemiology Biomarkers Prev*. 18: 3426-3434, 2009.

Mwenifumbo J and **Tyndale RF**. Molecular genetics of nicotine metabolism and pharmacology In *Nicotine Psychopharmacology: Handbook of Experimental Pharmacology*, JE Henningfield, ED London, S Pogun editors, Springer Publisher, Vol. 192, 235-259, 2009.

Ray R, **Tyndale RF**, Lerman C. Nicotine Dependence Pharmacogenetics: Role of Genetic Variation in Nicotine Metabolizing Enzymes. *J Neurogenetics*, 23:1-10, 2009.

Conti DV, Lewinger JP, Swan GE, **Tyndale RF**, Benowitz NL, Thomas PD. Using Ontologies in Hierarchical Modeling of Genes and Exposure in Biologic Pathways In: *Phenotypes, Endophenotypes, and Genetic Studies of Nicotine Dependence NCI Monograph 22*. pp 539-584, 2009.

Tyndale RF, Grant DM. Werner Kalow, MD (1917-2008). *The Rich Life of a Poor Metabolizer*.

In: McLeod HL, DeVane CL, Johnson JA, Knoell DL, Kolesar JM, McInerney JD, Rogers PD, Walker JR. Pharmacogenomics - Applications to Patient Care, 2nd Ed. ACCP: Kansas City, Missouri, pp 20-22, 2009.

Utrecht JP

Utrecht J. Immune-mediated adverse drug reactions. Chem. Res. Toxicol. 22: 24-34, 2009.

Li J, Mannargudi B, **Utrecht JP.** Covalent binding of penicillamine to macrophages: Implications for penicillamine-induced autoimmunity. Chem. Res. Toxicol. 22(7): 1277-1284, 2009.

Li J, **Utrecht JP.** D-Penicillamine-induced autoimmunity: relationship to macrophage activation. Chem. Res. Toxicol. 22(9): 1526-1533, 2009.

Mannargudi B, McNally D, Reynolds W, **Utrecht J.** Bioactivation of minocycline to reactive metabolites by myeloperoxidase, horseradish peroxidase and hepatic microsomes: implications for minocycline-induced lupus and hepatitis. Drug Metab. Dispos. 37(9): 1806-1818, 2009.

Utrecht J: Immunoallergic drug-induced liver injury in humans. Sem. Liver Dis. 29(4): 383-392, 2009.

Chen X, Tharmanathan T, Mannargudi B, Gou H, **Utrecht JP.** A study of the specificity of the lymphocytes in nevirapine-induced skin rash. J. Pharmacol. Exp. Ther. 331: 836-841, 2009.

Popovic M, Shenton JM, Chen J, Baban A, Tharmanathan T, Mannargudi B, Abdulla D, **Utrecht JP.** Nevirapine Hypersensitivity. In: Utrecht J (Ed) Adverse Drug Reactions, Springer, pp 437-452, 2009.

Li J, **Utrecht JP.** The Danger Hypothesis Applied to Idiosyncratic Drug Reactions, Utrecht J (Ed) Adverse Drug Reactions, Springer, pp 493-510, 2009.

Warsh JJ

Xu C, Li PP, Cooke RG, Parikh SV, Wang, KS, Kennedy JL, **Warsh JJ.** Genetic variation of TRPM2 and risk for bipolar disorder: Confirmation in a family-based association study. Bipolar Disorders, 11: 1-10, 2009.

Roedding AS, Gao AF, Wu AML, Li PP, Kish, SJ, **Warsh JJ.** TRPC3 protein is expressed across the lifespan in human prefrontal cortex and cerebellum., Brain Res. 1260:1-6, 2009

Perova T, Kwan M, Li PP, **Warsh JJ.** Differential modulation of intracellular Ca²⁺ responses in B lymphoblasts by mood stabilizers. Int J Neuropsychopharmacol. doi: 10.1017 /S1461145709000261 Epub ahead of print April 29, 2009

Wells PG

Chen CS, Squire JA and **Wells PG.** Reduced tumorigenesis in p53 knockout mice exposed *in utero* to low-dose vitamin E. Cancer, 115(7): 1563-1575, 2009

Kalliomäki T, McCallum GP, **Wells PG** and Hill RP. Progression and metastasis in a transgenic mouse breast cancer model: Effects of exposure to in vivo hypoxia. *Cancer Lett.* 282: 98-108, 2009.

Goncalves LL, Ramkisson A and **Wells PG**. Prostaglandin H synthase-1-catalyzed bioactivation of neurotransmitters, their precursors and metabolites: oxidative DNA damage and electron spin resonance spectroscopy studies. *Chem. Res. Toxicol.* 22(5): 842-852, 2009.

Preston TJ, Henderson JT, McCallum GP and **Wells PG**. Base excision repair of reactive oxygen species-initiated 7,8-dihydro-8-oxo-2'-deoxyguanosine inhibits the cytotoxicity of platinum anticancer drugs. *Mol. Cancer Ther.* 8(7): 2015-2026, 2009.

Wells PG, McCallum GP, Chen CS, Henderson JT, Lee CJJ, Perstin J, Preston TJ, Wiley MJ and Wong AW. Oxidative stress in developmental origins of disease: teratogenesis, neurodevelopmental deficits and cancer. *Toxicol. Sci.* 108(1): 4-18, 2009.

Wells PG, Lee CJJ, McCallum GP, Perstin J and Harper PA. Receptor- and reactive intermediate-mediated mechanisms of teratogenesis. In: "Handbook of Experimental Pharmacology", Vol. 196: Mechanisms of Adverse Drug Reactions, JP Uetrecht (ed.), pp. 131-162, Springer, Heidelberg, 2009.

Wong ACH

Kaminsky ZA, Tang T, Wang SC, Ptak C, Oh G, **Wong AHC**, Feldcamp LA, Virtanen C, Halfvarsson J, Tysk C, McRae A, Visscher P, Montgomery GW, Gottesman II, Martin NG, and Petronis A. DNA methylome studies in twins, *Nature Genetics*, 41, 240 - 245 2009

Rastogi A, Zai C, Likhodi O, Kennedy JL, **Wong AHC**. Genetic association and post-mortem brain mRNA analysis of the DISC1 gene in schizophrenia. *Schizophrenia Res* 114:39-49, 2009.

Labrie V, Fukumura R, Rastogi A, Lee FH, Baker GB, Belsham DD, Barger SW, Gondo Y, **Wong AHC**, Roder JC. Genetic inactivation of serine racemase produces behavioral phenotypes related to schizophrenia in mice. *Human Mol Genet.* 18: 3227-3243, 2009.

Haque FN, Gottesman II, **Wong AHC**: Not really identical: epigenetic differences in monozygotic twins and implications for twin studies in psychiatry. *Am J Med Gen: Seminars on Medical Genetics* 15; 151C(2):136-41, 2009.

De Luca V, Viggiano E, Dhoot R, Kennedy JL, **Wong AHC**: Methylation and QTDT analysis of the 5-HT2A receptor 102C allele: Analysis of suicidality in major psychosis, *J Psychiat Res.* 43: 532-537, 2009.

Zack M

Zack, M., Sharpley, J., Dent, C.W., & Stacy, A. W. Context effects and false memory for alcohol words in adolescents. *Addictive Behaviors*, 34, 327-330, 2009.

Zack, M., & Poulos, C.X. Parallel roles for dopamine in pathological gambling and psychostimulant addiction. *Current Drug Abuse Reviews*, 2, 11-25, 2009.

Zack, M., & Poulos, C.X. . Effects of the atypical stimulant modafinil on a brief gambling episode in pathological gamblers with high versus low impulsivity. *J Psychopharmacol.* 23:660-71, 2009.

Zawertailo L

Busto U, Redden L, Mayberg H, Houle S, Kapur S, **Zawertailo L.** Dopaminergic activity in depressed smokers: A PET study. *Synapse*, 63:681-689, 2009.

Ph.D. Theses (2009)

Balducci, X. (2009) Probing Mesocorticolimbic Dopamine Function in Alcohol Dependence Using Dextroamphetamine: Behavioral and fMRI Studies. Supervisors: Dr. C. Naranjo and Dr. B. Sproule.

Mwenifumbo, J. (2009). Cytochrome P450 2A6 Genetics and Nicotine Kinetics in a Population of Black African Descent. Supervisor: Dr. R.F. Tyndale.

Taha, A. (2009) Anticonvulsant Effects of Omega-3 Polyunsaturated Fatty Acids in Rodents. Supervisor: Dr. W.M. Burnham.

M.Sc. Theses (2009)

Chiuccariello, L. (2009) The Role of Dopamine in Cue-Induced Craving: A[11C]-(+)-PHNO PET Study In Tobacco-Dependent Smokers. Supervisor: Dr. U. Busto and Dr. B. Le Foll.

Dowlati, Y. (2009) Comparing Hair Cortisol in Coronary Artery Disease Patients with and Without Depressive Symptoms. Supervisor: Dr. K. Lanctôt.

Faheim, S. (2009) Impact of Genetic Polymorphisms Within the CYP2B6 Enzyme on Smoking Behaviors. Supervisor: Dr. R.F. Tyndale.

Haque, F.N. (2009) DISC1 Mutant Mice Subjected to Chronic Social Defeat Stress as a Model of Gene-Environment Interaction in Schizophrenia and Depression. Supervisor: Dr. A. Wong.

Kushnir, V. (2009) Investigating Smoking Cue Salience in Individuals with Comorbid Nicotine Dependence and Major Depressive Disorder: An fMRI Study. Supervisor: Dr. U. Busto.

Mattocks, M. (2009) Creation of a Transgenic Mouse Model Overexpressing $G\alpha_{11}$ in an Osteoblast-Specific Manner. Supervisor: Dr. J. Mitchell.

Mroziewicz, M. (2009) The Impact of CYP2A6 Genotype on Smoking Cessation in an Extended Nicotine Patch Therapy Clinical Trial. Supervisor: Dr. R. Tyndale.

Pansoy, A. (2009) New Insights Into the 3-Methylcholanthrene-Induced Chromatin Binding Profiles of Aryl Hydrocarbon Receptor and Estrogen Receptor Alpha. Supervisor: Dr. J. Matthews.

Shor, S. (2009) Use of Meconium and Hair for Detection of Prenatal Exposure to Ethanol and Other Drugs of Abuse. Supervisor: Dr. G. Koren.

Tremblay, A. (2009) Effects of Stress and Alcohol Cues on Incentive Salience and Inhibitory Control in Problem Drinkers and Healthy Controls. Supervisor: Dr. M. Zack.